Evidence map›Paper›PMID 41188645›Full record

ArticleNature biotechnology2025

KATMAP infers splicing factor activity and regulatory targets from knockdown data.

Michael P McGurk, David C McWatters, Christopher B Burge

Abstract read
PubMed Publisher
In one paragraph

Article in Nature biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Michael P McGurkDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA, US. mmcgurk@mit.edu.ORCID http://orcid.org/0000-0003-1938-4481
David C McWattersDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA, US.
Christopher B BurgeDepartment of Biology, Massachusetts Institute of Technology, Cambridge, MA, US. cburge@mit.edu.ORCID http://orcid.org/0000-0001-9047-5648

Funding

Identification and Function of Sequence-specific Splicing RegulatorsR01GM085319 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BURGE, CHRISTOPHER B · 2008 to 2025
$5.2M
Connecting perturbations of RNA binding proteins to their consequencesF32HG012307 · NHGRI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI MCGURK, MICHAEL P · 2022 to 2024
$218k
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (NHGRI) F32HG012307U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) R01GM085319
6 · The paper itself

Abstract

Typical RNA sequencing (RNA-seq) experiments uncover hundreds of splicing changes, reflecting underlying changes in splicing factor (SF) activity. Understanding how SF activity influences transcriptomic variation requires elucidating how each SF impacts splicing. Here, we present an interpretable regression model, KATMAP, which models splicing changes throughout the transcriptome by analyzing changes in SF binding and the resulting alterations in RNA processing. To learn a regulatory model, KATMAP requires SF perturbation RNA-seq data and the SF's binding motif as inputs, returning a description of the SF's position-specific regulatory activity and predicted targets. The KATMAP software includes models pretrained on ENCODE SF knockdown data. Learned KATMAP models can be applied to predict SF regulation and cis-elements at individual exons, which can guide the design of splice-switching antisense oligonucleotides. KATMAP can also interpret RNA-seq data by uncovering the factors responsible for transcriptomic changes, distinguishing direct SF targets from indirect effects and inferring relevant SFs from clinical RNA-seq data.

Identifiers

PMID41188645

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.